… development against this target. Alpha-synuclein clumps into, scientists believe, toxic aggregates that damage cells in Parkinson's disease … are hitting the right types of alpha-synuclein to stop PD. How do we measure alpha-synuclein? An objective, biological …

… Institute and Hospital in Canada, who leads much research into early PD detection, authored a commentary piece accompanying …

… School of Biomedical Engineering at Purdue University. His research interests include the miniaturization of mass … Ouyang has won a number of awards including the US NSF Early Career Award, the Coulter Foundation Early Career Award, the American Society for Mass Spectrometry Research Award, and the International Mass Spectrometry …

… Learn More Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN) Powering the Next Generation … the therapeutic and biomarker landscape—offering insights into emerging science, development progress, and MJFF’s role … MJFF is committed to supporting efforts that de-risk early-stage Parkinson's disease research to accelerate …

… Small a-synuclein aggregates are very toxic and may be an early indicator of the disease. We will develop ligands that … brain samples from pre-clinical models of PD. Relevance to Diagnosis/Treatment of Parkinson’s Disease: Aggregation of alpha-synuclein into small toxic structures is a key early step in the …

… has announced the launch of its LEAPS ( Linked Efforts to Accelerate Parkinson’s Solutions ) 2007 funding effort, committing up to $10 million to support ambitious research … cell technology to deliver GDNF, a trophic factor that has shown potential in preclinical trials to slow or stop PD …